Health
Biogen's Alzheimer’s Drug Shows Mixed Results
Biogen's tau-targeting Alzheimer's drug has shown mixed results in a mid-stage study, prompting the company to advance it into Phase 3 trials.
Coverage timeline — 1 article
STAT News
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
2026-05-14 11:08 UTC